Interactions between ranexa(ranolazine) and Azithromycin (azithromycin)
azithromycin and ranolazine (Major Drug-Drug)
CONTRAINDICATED: Ranolazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction. With repeat dosing, the mean effect of ranolazine (1000 mg twice daily) on QTc at Tmax is about 6 msec. However, in 5% of the population, the prolongation of QTc is 15 msec. The relationship between ranolazine plasma level and QTc remains linear over a concentration range up to 4-fold greater than the concentrations produced by a dosage of 1000 mg twice a day, and this relationship is not significantly affected by age, weight, gender, race, heart rate, congestive heart failure NYHA class, or diabetes.
MANAGEMENT: The concurrent use of ranolazine with other medications that can prolong the QT interval is considered contraindicated.
